(VIANEWS) – Southern Missouri Bancorp (SMBC), Entravision Communications Corporation (EVC), BioMarin Pharmaceutical (BMRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Southern Missouri Bancorp (SMBC)
35.6% sales growth and 13.69% return on equity
Southern Missouri Bancorp, Inc. operates as the bank holding company for Southern Bank that provides banking and financial services to individuals and corporate customers in the United States. It offers various deposit instruments, including interest-bearing and noninterest-bearing transaction accounts, money market deposit accounts, saving accounts, certificates of deposit, and retirement savings plans. The company also provides loans for the acquisition or refinance of one-to four-family residences and multi-family residential properties; loans secured by commercial real estate, such as farmland, single- and multi-tenant retail properties, restaurants, hotels, land, nursing homes and other healthcare-related facilities, warehouses and distribution centers, convenience stores, automobile dealerships and other automotive-related services, and other businesses; construction loans; and various secured consumer loans comprising home equity, direct and indirect automobile loans, second mortgages, mobile home loans, and loans secured by deposits. In addition, it offers commercial business loans, such as loans to finance accounts receivable, inventory, equipment, and operating lines of credit, which include agricultural production and equipment loans. As of June 30, 2020, the company operated 45 full-service branch offices, and two limited-service branch offices located in Poplar Bluff, Van Buren, Dexter, Kennett, Doniphan, Sikeston, Qulin, Matthews, Springfield, Thayer, West Plains, Alton, Clever, Forsyth, Fremont Hills, Kimberling City, Ozark, Nixa, Rogersville, Marshfield, Cape Girardeau, Jackson, Gideon, Chaffee, Benton, Advance, Bloomfield, Essex, and Rolla Missouri; Jonesboro, Paragould, Batesville, Searcy, Bald Knob, Bradford, and Cabot, Arkansas; and Anna, Cairo, and Tamms, Illinois. Southern Missouri Bancorp, Inc. was founded in 1887 and is headquartered in Poplar Bluff, Missouri.
Earnings Per Share
As for profitability, Southern Missouri Bancorp has a trailing twelve months EPS of $4.73.
PE Ratio
Southern Missouri Bancorp has a trailing twelve months price to earnings ratio of 7.65. Meaning, the purchaser of the share is investing $7.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.69%.
Previous days news about Southern Missouri Bancorp(SMBC)
- According to Zacks on Thursday, 27 April, "Another stock from the same industry, Southern Missouri Bancorp (SMBC Quick QuoteSMBC – Free Report) , has yet to report results for the quarter ended March 2023."
2. Entravision Communications Corporation (EVC)
13.5% sales growth and 7.44% return on equity
Entravision Communications Corporation operates as an advertising, media, and technology solutions company worldwide. The company operates through three segments: Digital, Television, and Audio. It reaches and engages Hispanics across acculturation levels and media channels. The company's portfolio encompasses integrated end-to-end advertising solutions, including digital, television, and audio properties. It also offers a suite of end-to-end digital advertising solutions, including digital commercial partnerships services, as well as advertising customers billing and technological and other support services, including strategic marketing and training; and Smadex, a programmatic ad purchasing platform that enables advertising customers or ad agencies to purchase advertising electronically and manage data-driven advertising campaigns through online marketplaces. In addition, the company provides a branding and mobile performance solutions, such as managed services to advertisers looking to connect with consumers on mobile devices; and digital audio advertising solutions for advertisers. Further, it sells advertisements and syndicated radio programming solutions through its Entravision radio network. As of March 3, 2022, the company had 50 television stations; and 46 Spanish-language radio stations. It serves advertisers from various industries, such as e-commerce, retail, entertainment, gaming, delivery services, financial technology, communications, lifestyle, and travel. The company was founded in 1996 and is headquartered in Santa Monica, California.
Earnings Per Share
As for profitability, Entravision Communications Corporation has a trailing twelve months EPS of $0.21.
PE Ratio
Entravision Communications Corporation has a trailing twelve months price to earnings ratio of 29.76. Meaning, the purchaser of the share is investing $29.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.44%.
Yearly Top and Bottom Value
Entravision Communications Corporation’s stock is valued at $6.25 at 16:23 EST, way under its 52-week high of $7.33 and way higher than its 52-week low of $3.96.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26.7%, now sitting on 956.21M for the twelve trailing months.
3. BioMarin Pharmaceutical (BMRN)
12.9% sales growth and 3.19% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.76.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 129.49. Meaning, the purchaser of the share is investing $129.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.19%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 68.3% and positive 66.7% for the next.
Previous days news about BioMarin Pharmaceutical(BMRN)
- According to Zacks on Thursday, 27 April, "For the quarter ended March 2023, BioMarin Pharmaceutical (BMRN Quick QuoteBMRN – Free Report) reported revenue of $596.42 million, up 14.8% over the same period last year. "
4. Eli Lilly and Company (LLY)
12.2% sales growth and 62.67% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $6.89.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 58.05. Meaning, the purchaser of the share is investing $58.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 62.67%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Feb 13, 2023, the estimated forward annual dividend rate is 4.52 and the estimated forward annual dividend yield is 1.17%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.7%, now sitting on 28.54B for the twelve trailing months.
Volume
Today’s last reported volume for Eli Lilly and Company is 3354280 which is 2.65% above its average volume of 3267490.
Yearly Top and Bottom Value
Eli Lilly and Company’s stock is valued at $399.95 at 16:23 EST, higher than its 52-week high of $386.27.
Previous days news about Eli Lilly and Company(LLY)
- According to Zacks on Thursday, 27 April, "Eli Lilly and Company price-consensus-eps-surprise-chart | Eli Lilly and Company Quote"
5. Westinghouse Air Brake Technologies Corporation (WAB)
8.3% sales growth and 6.29% return on equity
Westinghouse Air Brake Technologies Corporation provides technology-based equipment, systems, and services for the freight rail and passenger transit industries worldwide. It operates through two segments, Freight and Transit. The Freight segment manufactures and services components for new and existing freight cars and locomotives; builds new commuter locomotives; rebuilds freight locomotives; supplies railway electronics, positive train control equipment, signal design, and engineering services; and provides related heat exchange and cooling systems. It serves publicly traded railroads; leasing companies; manufacturers of original equipment, including locomotives and freight cars; and utilities. The Transit segment manufactures and services components for new and existing passenger transit vehicles, such as regional trains, high speed trains, subway cars, light-rail vehicles, and buses; refurbishes subway cars; and provides heating, ventilation, and air conditioning equipment, as well as doors for buses and subways. This segment serves public transit authorities and municipalities, leasing companies, and manufacturers of subway cars and buses. It also provides electronically controlled pneumatic braking products; railway electronics; freight car trucks; draft gears, couplers, and slack adjusters; air compressors and dryers; heat exchangers and cooling products; and track and switch products. In addition, the company offers railway braking equipment and related components; friction products; new switcher locomotives; transit locomotive and car overhaul services; and freight locomotive overhaul, modernizations, and refurbishment services. Further, it provides platform screen doors; pantographs; window assemblies; couplers; accessibility lifts and ramps for buses and subway cars; and traction motors. The company was founded in 1869 and is headquartered in Pittsburgh, Pennsylvania.
Earnings Per Share
As for profitability, Westinghouse Air Brake Technologies Corporation has a trailing twelve months EPS of $3.46.
PE Ratio
Westinghouse Air Brake Technologies Corporation has a trailing twelve months price to earnings ratio of 28.92. Meaning, the purchaser of the share is investing $28.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.29%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 6.2% and 6.5%, respectively.
Previous days news about Westinghouse Air Brake Technologies Corporation(WAB)
- According to Zacks on Wednesday, 26 April, "Westinghouse Air Brake Technologies Corporation price-consensus-eps-surprise-chart | Westinghouse Air Brake Technologies Corporation Quote"
6. Dycom Industries (DY)
6% sales growth and 17.48% return on equity
Dycom Industries, Inc. provides specialty contracting services in the United States. The company offers various specialty contracting services, including program management, engineering, construction, maintenance, and installation services, such as placement and splicing of fiber, copper, and coaxial cables to telecommunications providers. It also provides tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; and installs and maintains customer premise equipment, such as digital video recorders, set top boxes, and modems for cable system operators. In addition, the company offers construction and maintenance services for electric and gas utilities, and other customers; and underground facility locating services, such as locating telephone, cable television, power, water, sewer, and gas lines for various utility companies, including telecommunication providers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.
Earnings Per Share
As for profitability, Dycom Industries has a trailing twelve months EPS of $4.79.
PE Ratio
Dycom Industries has a trailing twelve months price to earnings ratio of 19.25. Meaning, the purchaser of the share is investing $19.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.48%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 3.81B for the twelve trailing months.
